Examples of TPPs that were developed to specifically target EGFR were previously reported; these species were shown to facilitate enhanced tumor selectivity and intratumoral delivery of therapeutic agents in EGFR-overexpressing malignancies [34,35,36]. This evidence concerns the gene EGFR and neoplasm.